The purpose of this Study is to better understand the demographic and clinical characteristics of PAH patients treated with Uptravi, to learn about the dosing and titration patterns of Uptravi (including any transition from other PAH specific therapies to Uptravi and from Uptravi to other prostanoids), and to describe the clinical course of patients treated with Uptravi.